• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

PM: Cambodians to receive AstraZeneca 3rd dose as 'booster'

firstwordpharmaAugust 02, 2021

Tag: PM , AstraZeneca , COVID-19 Vaccines

Cambodia prime minister Hun Sen said that the country will implement booster doses with COVID-19 vaccines, beginning with frontline workers, Khmer Times reported Sunday.

PM: Cambodians to receive AstraZeneca 3rd dose as 'booster'

Specifically, AstraZeneca's vaccine will be used as a booster for those previously immunised with shots from Sinopharm or Sinovac.

Meanwhile, people initially immunised with AstraZeneca's vaccine, will receive Sinopharm or Sinovac for their third dose.


Previous:Sputnik V vaccine production in India to go fully on stream in September: RDIF

Next:Research body recommends COVID-19 drug

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

PM: Cambodians to receive AstraZeneca 3rd dose as 'booster' | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

1,6-Hexanediol diacrylate (stabilized with 100 ppm MEHQ)

1,6-Hexanediol diacrylate (stabilized with 100 ppm MEHQ)
P-SPM Sphingomyelin

P-SPM Sphingomyelin
Factory direct supply organic solvent dipropylene glycol methyl ether DPM best price fast delivery C

Factory direct supply organic solvent dipropylene glycol methyl ether DPM best price fast delivery C
ATPM HCl

ATPM HCl
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins
CEFADROXIL cephalosporins

CEFADROXIL cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service